CRISPR Therapeutics presents zugo-cel lymphoma data at ASH annual meeting
CRSP•CRISPR Therapeutics will present Phase 1/2 zugo-cel data for relapsed or refractory large B-cell lymphoma at the ASH annual meeting on Dec. 13, 2026.
1. Presentation scheduled
CRISPR Therapeutics will give an oral presentation on Phase 1/2 results for zugo-cel in relapsed or refractory large B-cell lymphoma on Dec. 13 at 5:15 p.m. CST. The American Society of Hematology annual meeting runs Dec. 12-15, 2026.
